The P-III (EMPACT-MI) study (part of the EMPOWER program) assesses the effect of Jardiance (10mg, QD) vs PBO alongside SoC administered within 14 days of hospitalization to prevent the risk of heart failure & mortality in adults (n=6,500) post heart attack
The study demonstrated a risk reduction of 10% in the time to first hospitalization due to heart failure or all-cause mortality with Jardiance that was not significant
The pre-specified exploratory analysis depicted a 23% of relative risk reduction in the time to first hospitalization & 33% for total hospitalizations due to heart failure. The results were highlighted at American College of Cardiology 2024 & published in the NEJM
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Boehringer Ingelheim’s Jardiance Receives NICE Recommendation for Symptomatic Chronic Heart Failure with Preserved or Mildly Reduced Ejection Fraction
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
